Biosimilar Development Editorial Board

Source: Biosimilar Development

Molly Burich, Director, Public Policy: Biosimilars and Reimbursement, Boehringer Ingelheim

Hubert C. Chen, MD
Medical and Scientific Advisor,
Pfenex

Hillel Cohen,
Executive Director,
Scientific Affairs,
Sandoz

Ross Day, Consulting Hospital Pharmacist, Former Director of Pharmacy, Vizient

Colin C. Edgerton, MD FACP FACR, Executive Chairman, American Rheumatology Network

Edric Engert, Managing Director, Abraxeolus Consulting

Francois-Xavier Frapaise, M.D., ClinExcel

Matthew Harman, PharmD, MPH, Director of Pharmacy, Employers Health

HoUng Kim,
Head of Strategy and
Operations,
Celltrion

Brian Lehman, MBA, MHA, RPh., Director, Medical Account Management and Strategic Alliances, Sandoz

Rick Lozano, VP, Biosimilars & Integrated Business Development, AmerisourceBergen

Julie Maréchal-Jamil, Director Biosimilars Policy & Science,
Medicines for Europe

Sue Naeyaert, Consultant, Former Global Government Affairs, Policy, and Pharmacoeconomics, Biosimilars, Fresenius Kabi

Ned Pojskic, Leader, Pharmacy & Health Provider Relations
Green Shield Canada

Erika Satterwhite, Head of Global Biosimilars Policy,
Mylan

Don Stewart, CEO,
PlantForm

Alexandra Valenti, Partner, Goodwin Procter LLP

Lauren Vela, Senior Director, Pacific Business Group on Health